{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:12:20Z","timestamp":1792811540239,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40265-022-01678-3","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T14:08:05Z","timestamp":1645193285000},"page":"341-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":164,"title":["Efgartigimod: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"issue":"10","key":"1678_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","volume":"17","author":"JD Lunemann","year":"2021","unstructured":"Lunemann JD. Getting specific: targeting Fc receptors in myasthenia gravis. Nat Rev Neurol. 2021;17(10):597\u20138.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1678_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113\u201324.","journal-title":"Nat Rev Neurol"},{"key":"1678_CR3","doi-asserted-by":"publisher","first-page":"175628642199738","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.","journal-title":"Ther Adv Neurol Disord"},{"key":"1678_CR4","unstructured":"argenx. FDA approves new treatment for myasthenia gravis [media release]. 17 Dec 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-myasthenia-gravis."},{"key":"1678_CR5","unstructured":"argenx. argenx announces VYVGART\u2122 approval in Japan for the treatment of generalized myasthenia gravis [media release]. 20 Jan 2022. https:\/\/www.argenx.com\/."},{"key":"1678_CR6","unstructured":"argenx. Vyvgart\u2122 (efgartigimod alfa-fcab) injection, for intravenous use: US highlights of prescribing information. 2021. https:\/\/argenx.com\/product\/vyvgart-prescribing-information.pdf. Accessed 13 Jan 2022."},{"issue":"Suppl 1","key":"1678_CR7","first-page":"S91","volume":"64","author":"J Guptill","year":"2021","unstructured":"Guptill J, Sleasman J, Steeland S, et al. Effect of efgartigimod, a neonatal fc receptor blocker, on humoral vaccine responses in autoimmune patients [abstract]. Muscle Nerve. 2021;64(Suppl 1):S91.","journal-title":"Muscle Nerve"},{"key":"1678_CR8","unstructured":"arGEN-X. arGEN-X announces non-exclusive license with BioWa for POTELLIGENT\u00ae technology [media release]. 26 Jul 2011. http:\/\/www.biowa.com."},{"key":"1678_CR9","unstructured":"arGEN-X. arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders [media release]. 24 Apr 2013. http:\/\/www.argen-x.com."},{"key":"1678_CR10","unstructured":"arGEN-X. arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B [media release]. 4 Nov 2013. http:\/\/www.arGEN-X.com."},{"key":"1678_CR11","unstructured":"Lonza, arGEN-X. Lonza and arGEN-X announce a multi-product GS XceedTM license agreement for therapeutic antibodies [media release]. 18 Feb 2015. http:\/\/www.lonza.com."},{"key":"1678_CR12","unstructured":"argenx, Halozyme Therapeutics. argenx and Halozyme enter global collaboration and license agreement for ENHANZE\u00ae technology [media release]. 4 Feb 2019. http:\/\/www.argenx.com."},{"key":"1678_CR13","unstructured":"Halozyme Therapeutics, argenx. Halozyme announces expansion of collaboration and license agreement with argenx for ENHANZE\u00ae technology [media release]. 5 Oct 2020. http:\/\/www.halozyme.com."},{"key":"1678_CR14","unstructured":"argenx. argenx enters into agreement to acquire Priority Review Voucher [media release]. 23 Nov 2020. http:\/\/www.argenx.com."},{"key":"1678_CR15","unstructured":"argenx, ZAI Lab. argenx and Zai Lab announce strategic collaboration for efgartigimod in Greater China [media release]. 6 Jan 2021. http:\/\/www.argenx.com."},{"key":"1678_CR16","unstructured":"Hansa Biopharma AB, argenx. Hansa Biopharma enters preclinical research collaboration with argenx [media release]. 29 Mar 2021. http:\/\/www.hansabiopharma.com."},{"key":"1678_CR17","unstructured":"Elektrofi, argenx. Elektrofi enters global collaboration and license agreement with argenx to explore new subcutaneous product formulations [media release]. 20 Apr 2021. http:\/\/www.elektrofi.com."},{"key":"1678_CR18","doi-asserted-by":"crossref","unstructured":"argenx. argenx reports third quarter 2021 financial results and provides business update [media release]. 28 Oct 2021. http:\/\/www.argenx.com.","DOI":"10.1016\/j.fopow.2021.11.012"},{"issue":"10","key":"1678_CR19","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386.","journal-title":"J Clin Invest"},{"key":"1678_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","volume":"317","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Plomp JJ, van Es IE, et al. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol. 2019;317:133\u201343.","journal-title":"Exp Neurol"},{"issue":"7","key":"1678_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1678_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, Sanchez-Gonzalez B, Rejto L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178\u201387.","journal-title":"Am J Hematol"},{"key":"1678_CR23","first-page":"05","volume":"05","author":"M Goebeler","year":"2021","unstructured":"Goebeler M, Bata-Csorgo Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2021;05:05.","journal-title":"Br J Dermatol"},{"key":"1678_CR24","unstructured":"argenx. argenx announces data from phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation [media release]. 14 Jun 2018. http:\/\/www.argenx.com."},{"issue":"Suppl 1","key":"1678_CR25","first-page":"S92","volume":"64","author":"C Karam","year":"2021","unstructured":"Karam C, Vu T, Bril V, et al. Efgartigimod treatment of patients with generalized myasthenia gravis demonstrates consistent improvements across all muscle subgroups and regardless of background immunosuppressive therapy [abstract]. Muscle Nerve. 2021;64(Suppl 1):S92.","journal-title":"Muscle Nerve"},{"issue":"23","key":"1678_CR26","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"issue":"15 Suppl","key":"1678_CR27","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1212\/WNL.94.15_supplement.4484","volume":"94","author":"J Howard","year":"2020","unstructured":"Howard J, Bril V, Mantegazza R, et al. Additional analyses of the phase 2 efgartigimod study in myasthenia gravis [abstract no. 4484]. Neurology. 2020;94(15 Suppl):4484.","journal-title":"Neurology"},{"key":"1678_CR28","unstructured":"argenx. argenx highlights strategic priorities for 2022 [media release]. 7 Jan 2022. http:\/\/www.argenx.com."}],"updated-by":[{"DOI":"10.1007\/s40265-022-01712-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01678-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01678-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01678-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T21:47:22Z","timestamp":1726696042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01678-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01678-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-022-01712-4","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"18 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01712-4","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01712-4","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}